San Francisco Bay Area biotech stories.
Thursday, March 17, 2011
FibroGen lands $40M milestone from Astellas
FibroGen Inc. received a $40 million milestone payment from Astellas Pharma Inc. as its investigational anemia therapy for chonic kidney disease patients advanced to Phase IIb studies.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)